Home Compare EXEL vs NOVN.SW
Stock Comparison · Comparison

Exelixis vs Novartis: Which Stock Looks Stronger in 2026?

Exelixis holds the cleaner structural position, with the lead spread across growth and valuation. Novartis still has the edge on stability, which keeps the comparison from looking entirely one-sided. The market setup is mixed, without a decisive signal in either direction. The market is not adding a decisive signal either way — the structural read carries the weight.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

This is not just a one-metric split: both growth and valuation materially support the lead. Exelixis, Inc. leads by 22 points on the overall comparison score.

Trajectory Similarity
0.74
Similar
Peer-set rank: #3
within Exelixis, Inc.'s functional peer set

This pair is matched through long-term financial trajectory similarity within the selected peer universe.

This level of similarity signals a strong structural match, even though some dimensions still separate the two companies.

The match is driven mainly by capital structure and revenue growth trajectory.

Similarity drivers
capital structurerevenue growth trajectory
How to read the score
0.85–1.00 · Very similar0.70–0.84 · Similar0.55–0.69 · Moderately similarbelow 0.55 · Loose match
Peer-Relative Score
EXEL
Exelixis, Inc.
77
Peer-Score
Signal qualityHigh
vs
NOVN.SW
Novartis AG
55
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

Score differences across key dimensions.

Dimension spread: EXEL vs NOVN.SW Profitability 83 60 Stability 65 78 Valuation 83 55 Growth 73 22 EXEL NOVN.SW
Gap Ranking
#1 Growth +51
#2 Valuation +28
#3 Profitability +23
#4 Stability +13
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for EXEL and NOVN.SW Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer EXELNOVN.SW Relative valuation Structural strength

Exelixis, Inc. looks stronger both structurally and on relative valuation.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Growth
On growth, Exelixis, Inc. ranks near the top of the group; Novartis AG sits in the weaker half.
Valuation
On valuation, the edge is clear — both rank well, but Exelixis, Inc. sits noticeably higher.
Growth — Dominant Gap
EXEL
73
NOVN.SW
22
Gap+51in favour of EXEL

Earnings growth is one contributing factor within the growth lead.

What keeps the gap from being one-sided

Novartis AG still carries lower volatility exposure — that difference is real enough to prevent the comparison from becoming one-sided.

What this means for the comparison

The lead is built on both growth and valuation — though stability still provides a counterweight.

Explore full peer positioning in AssetNext

Break down the EXEL vs NOVN.SW comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar growth-and-valuation comparisons

Explore how EXEL and NOVN.SW each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.